Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2016 Apr 18

PMID 27086140

Citations 5

Authors

Jeffrey Betcher

Elizabeth Dow

Nandita Khera

Affiliations

Soon will be listed here.

Abstract

Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the need for proactive involvement of all stakeholders to optimize adherence for successful use of these agents are increasingly being recognized. The current reactive model is negatively impacting the patient experience through delays in care, financial toxicity, and decreased safety. It also impacts the healthcare providers in the form of lost revenue and staff burnout due to labor-intensive procurement and patient financial assistance burdens. In this review, we describe some of the issues identified and discuss potential strategies to improve patient access, minimize healthcare burden, and review current policy initiatives and patient advocacy efforts to reduce financial toxicity.

Citing Articles

Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.

Vyas A, Descoteaux A, Kogut S, Parikh M, Campbell P, Green A J Manag Care Spec Pharm. 2022; 28(8):831-844.

PMID: 35876294 PMC: 10372994. DOI: 10.18553/jmcp.2022.28.8.831.

A mixed method study design to explore the adherence of haematological cancer patients to oral anticancer medication in a multilingual and multicultural outpatient setting: The MADESIO protocol.

Michiels S, Tricas-Sauras S, Dauvrin M, Bron D, Kirakoya-Samadoulougou F PLoS One. 2021; 16(6):e0253526.

PMID: 34166438 PMC: 8224871. DOI: 10.1371/journal.pone.0253526.

Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty.

Hilal T, Betcher J, Leis J Curr Hematol Malig Rep. 2018; 13(4):237-243.

PMID: 29982866 DOI: 10.1007/s11899-018-0461-y.

Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations.

Paolella G, Boyd A, Wirth S, Cuellar S, Venepalli N, Crawford S Pharmacy (Basel). 2018; 6(1).

PMID: 29518017 PMC: 5874562. DOI: 10.3390/pharmacy6010023.

Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.

Shen C, Zhao B, Liu L, Shih Y Cancer. 2017; 124(2):364-373.

PMID: 28976559 PMC: 5764158. DOI: 10.1002/cncr.31050.

References

Ubel P, Abernethy A, Zafar S . Full disclosure--out-of-pocket costs as side effects. N Engl J Med. 2013; 369(16):1484-6. DOI: 10.1056/NEJMp1306826. View

Barillet M, Prevost V, Joly F, Clarisse B . Oral antineoplastic agents: how do we care about adherence?. Br J Clin Pharmacol. 2015; 80(6):1289-302. PMC: 4693496. DOI: 10.1111/bcp.12734. View

Bhatia S, Landier W, Shangguan M, Hageman L, Schaible A, Carter A . Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2012; 30(17):2094-101. PMC: 3601449. DOI: 10.1200/JCO.2011.38.9924. View

Liu G, Franssen E, Fitch M, Warner E . Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15(1):110-5. DOI: 10.1200/JCO.1997.15.1.110. View

Shen C, Chien C, Geynisman D, Smieliauskas F, Shih Y . A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014; 14(1):45-69. DOI: 10.1586/14737167.2014.868310. View

DeMario M, Ratain M . Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998; 16(7):2557-67. DOI: 10.1200/JCO.1998.16.7.2557. View

Tefferi A, Kantarjian H, Rajkumar S, Baker L, Abkowitz J, Adamson J . In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015; 90(8):996-1000. PMC: 5365030. DOI: 10.1016/j.mayocp.2015.06.001. View

McCue D, Lohr L, Pick A . Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy. 2014; 34(5):481-94. DOI: 10.1002/phar.1399. View

Suchanek D . The rise and role of specialty pharmacy. Biotechnol Healthc. 2013; 2(5):31-5. PMC: 3571003. View

10.

Partridge A, Avorn J, Wang P, Winer E . Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002; 94(9):652-61. DOI: 10.1093/jnci/94.9.652. View

11.

Bhatia S, Landier W, Hageman L, Kim H, Chen Y, Crews K . 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2014; 124(15):2345-53. PMC: 4192748. DOI: 10.1182/blood-2014-01-552166. View

12.

. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013; 121(22):4439-42. PMC: 4190613. DOI: 10.1182/blood-2013-03-490003. View

13.

Bedell C . A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2004; 7(6 Suppl):5-9. DOI: 10.1188/03.CJON.S6.5-9. View

14.

Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C . Development of the MASCC Teaching Tool for Patients Receiving Oral Agents for Cancer. Support Care Cancer. 2009; 18(5):583-90. DOI: 10.1007/s00520-009-0692-5. View

15.

Esper P . Identifying strategies to optimize care with oral cancer therapy. Clin J Oncol Nurs. 2013; 17(6):629-36. DOI: 10.1188/13.CJON.629-636. View

16.

Waterhouse D, Calzone K, Mele C, Brenner D . Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993; 11(6):1189-97. DOI: 10.1200/JCO.1993.11.6.1189. View

17.

Jabbour E, Saglio G, Radich J, Kantarjian H . Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk. 2012; 12(4):223-9. PMC: 4428159. DOI: 10.1016/j.clml.2012.04.002. View

18.

Ruddy K, Mayer E, Partridge A . Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59(1):56-66. DOI: 10.3322/caac.20004. View

19.

Greer J, Amoyal N, Nisotel L, Fishbein J, MacDonald J, Stagl J . A Systematic Review of Adherence to Oral Antineoplastic Therapies. Oncologist. 2016; 21(3):354-76. PMC: 4786357. DOI: 10.1634/theoncologist.2015-0405. View

20.

Weingart S, Brown E, Bach P, Eng K, Johnson S, Kuzel T . NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw. 2008; 6 Suppl 3:S1-14. View